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1. Introduction
The growth in the number of registered clinical trials indi-
cates that there is a need for cells for many types of cell
therapy. Figure 1, which is reprinted from the excellent blog
maintained by Alexi Bersenev, shows that the cell type used
in most clinical trials worldwide is the mesenchymal stromal
cell (MSC).TheMSC type requires in vitro expansion to reach
a clinical dose and thus there is a desire to optimize and
standardize processes and procedures for MSC manufacture
specifically for clinical use.
When considering MSC, there are “issues” associated
with manufacturing which warrant special consideration.
Some of these issues are associated with the identification
of the MSC source used for therapeutic cells because MSCs
can be isolated from different tissues. For example, they can
be isolated from fat, bone marrow, or fetal tissues such as
placenta or umbilical cord. For autologous use, MSCs from
fat have received attention.MSCs can be isolated fromdonors
of different age or sex. Finally, the health status of the donor
may affect MSC function. These factors may affect MSC
isolation, expansion capability, function, and/or survival after
transplantation.Thus,MSCs from one tissue may be superior
to MSCs from another for a particular clinical application.
However, if one cannot expand the MSCs to a therapeutic
dose, it moots the point.
Much attention has focused upon manufacturing or
expanding MSCs for clinical use. There is a lack of standard-
izationwithMSC characterization, as recently reviewed [1, 2].
Some researchers suggested that “standardized” MSCs be
derived, expanded, and provided to the research community
as a means of addressing the differences in MSC character-
ization found between laboratories [2, 3]. Other researchers
suggested that standardization of the characterization meth-
ods and tools is needed [1]. When one considers that MSC
manufacturing and passaging contribute to the differences
mentioned above, for example, MSCs isolated from different
passages [4, 5] or from donors of different tissues, ages,
or health status reflecting the inherent biological variability,
MSCs might defy standardization [2, 6–8]. As a first step,
it might be easiest to establish standardized characterization
tools and protocols or perhaps to use a certification procedure
to make the characterization of MSCs between laboratories
more uniform.
In this issue, eight articles address different aspects of
manufacturing cells for cell therapy. These articles can be
broken down into two groups. The first group deals with
scale-up and manufacturing of MSCs and consists of five
papers (those of J. R. Smith et al., F. Petry et al., D. Salzig et al.,
R. J. Emnett et al., andV. Jossen et al.).The second group deals
with application and optimizing of cell therapy and consists
of three papers (those of N. E. Rekittke et al., S. Zhou et al.,
and J. E. V. Meraz et al.).
2. Manufacturing MSCs for Clinical Use
J. R. Smith et al. focused efforts to standardize and opti-
mize the isolation of MSCs from the umbilical cord. They
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Figure 1: Number of stem cell therapy trials by cell type worldwide
(reprinted from [9]).
developed a process to extract cells using Miltenyi C-tubes
coupled with enzymatic digestion with minimal dissection
that resulted in 10x more MSCs than their previously
described method, while also reducing contamination risk.
They expanded theMSCs in xenogeneic-material-free condi-
tions using 10% pooled human platelet lysate to supplement
the growthmedium.MSCs produced using their newmethod
met the minimal definition of MSCs set by ISCT’s MSC
working group. They also had one unexpected finding: a
higher yield of MSCs from cords derived from natural
births compared to Caesarian-section births. They did not
identify the mechanism responsible. Taken together, their
findings provided a more streamline extraction method and
an optimized expansion protocol suitable for translation
to clinical manufacturing. The main limitation for clinical
translation is the use of enzymatic digestion.
The contribution by F. Petry et al. involves the growth
of MSCs in three dimensions (3D) with scale-up to clinical
manufacturing in a stirred tank bioreactor. They started the
scale-up by identifying microcarriers that would be suitable
to the umbilical cord MSCs in small-scale spinner flasks.
Interestingly, the umbilical cord MSCs preferred a plastic
microcarrier, as opposed to the treated glassmicrocarrier that
telomerase immortalized bone marrow MSCs prefer [10–12].
It appears thatMSCs fromdifferent tissue sources have differ-
ent attachment requirements. Or perhaps the differences are
due to the use of pooled human platelet lysate as a medium
additive in F. Petry et al.’s paper compared to fetal bovine
serum used to expand the bonemarrow-derivedMSCs. After
identifying the best microcarrier, F. Petry et al. tested seeding
protocols and feeding strategies in spinner flasks. The paper
culminated in scale-up to 2.5 L in a Millipore Mobius single
use stirred tank bioreactor. This paper identified scaling
factors and set the stage for more highly refined optimization
and an SOP for MSC expansion. The MSCs produced in 3D
met the minimal definition of MSCs and were not obviously
different from the MSCs expanded in 2D in their companion
paper (J. R. Smith et al.).
The paper by D. Salzig et al. involved the optimization
of MSC expansion in chemically defined medium (CDM)
for GMP manufacturing. The use of a chemically defined
medium might eliminate the need for batch-to-batch com-
parison and validation of medium which employs biologics.
D. Salzig et al. compared the growth of both an immortalized
MSC line and primary MSCs from bone marrow or adipose
tissues in CDM following various surface treatments of the
substrate to enhance attachment. They found a difference
in the surface attachment requirements between the MSC
types. For example, bone marrow-derived MSCs did not
attach rapidly in CDM, compared to immortalized MSCs or
adipose-derivedMSCs that attached in 2–5 hrs. Immortalized
MSCs attached readily to specialized tissue culture plastic
in CDM and grew as well as or better than MSCs seeded
onto standard tissue culture plastics in serum containing
medium. In contrast, surface coating with collagen type IV or
fibronectin, but not laminin,was important for bonemarrow-
derived MSC’s attachment and growth. Interestingly, for the
bone marrow MSCs, D. Salzig et al. were unable to achieve
MSC expansion equal to serum containing medium. Next,
they evaluated the detachment efficiency of four different
enzymes (trypsin, accutase, prolyl-specific peptidase (PsP),
and collagenase) on bonemarrow-derivedMSCs and immor-
talized MSCs. Again, they found differences between MSCs
source and the type of medium on the detachment efficiency.
For immortalized MSCs, CDM reduced the efficiency to
detach, compared to serum containing medium, and colla-
genase was inferior to trypsin, accutase, and PsP. In contrast,
all four enzymes performed equally well for detaching bone
marrow-derived MSCs grown in serum containing medium,
with little or no effect of surface treatment. These results
indicate that derivation of SOPs for MSC expansion and
harvestmight need to be customized for each type ofmedium
used and MSCs tissue source. The data in this paper argues
against the notion that standardized conditions forMSCs can
be generalized across tissue source.
R. J. Emnett et al. developed a GMP-compliant method to
isolatemesenchymal stromal cells (MSCs) from the umbilical
cord. Since many of the currently described methods use
enzymatic digestion to extract cells from the cord and since
that step introduces xenogeneic reagents, R. J. Emnett et
al. were determined to extract MSCs following mechanical
disruption of the cord using a tissue homogenizer and they
compared the yield to that obtained following collagenase
digestion. Next, they expanded MSCs in medium supple-
mented with 10% pooled human platelet lysate or 20%
fetal bovine serum. They found that mechanical disruption
produced an identical yield as collagenase extraction at the
initial isolation step. However, following expansion, fewer
cells were produced after mechanical dissociation compared
to enzymatic extraction. Mechanical extraction may have
Stem Cells International 3
introduced higher levels of cellular stress and this could have
produced the observed slower expansion at both early pas-
sage (P1–P3) and later passage (P7–P9). Mechanical dissocia-
tion impaired colony-forming efficiency of MSCs compared
toMSCs enzymatically extracted whenMSCs were expanded
in pooled human platelet lysate, also suggesting that MSCs
isolated by mechanical disruption were stressed. R. J. Emnett
et al. calculated that they could theoretically reach their
manufacturing goals of 30 billionMSCswithin approximately
one month of culture for either method. Their method is
easily scaled up, requires minimal manipulation of the cord
tissues prior to extraction within a closed system, and pro-
ducesMSCs that meet the ISCT definition for surface marker
expression and trilineage differentiation. While additional
characterizationwork would be needed to validate thatMSCs
expanded following mechanical extraction are bioequivalent
to MSCs expanded following enzymatic isolation methods,
the simplicity of this method is encouraging and easily
standardized between laboratories.
V. Jossen et al. examined the expansion of human
adipose-derived MSCs on microcarriers for manufacturing
scale-up in both stirred tank bioreactor and a bag (wave-
mixer type) bioreactor. Their intent was to investigate the
relationship between impeller speed and shear stress and to
minimize the aggregation of microcarriers which is thought
to result in limitations of mass transfer and heterogeneous
distribution of cells on the carriers. Further, aggregation
of carriers may interfere with the use of computational
methods to model scale-up results. Here, V. Jossen et al. used
adipose-derivedMSCs from a single donor.TheseMSCswere
expanded in Lonza specialty medium supplemented with
5% fetal bovine serum using polystyrene microcarriers. The
authors found the largest expansion factor at impeller speeds
that were slower than the suspension speed (Ns1), at a speed
they term Nsiu. It should be noted that Ns1 (sometimes called
NSJ) is used in the industry as an accepted impeller speed
since this is the minimal speed to suspend the carriers in the
fluid column, thereby maximize mass transfer, and minimize
the possibility of heterogenous distribution of cells on the car-
riers. The authors show enhanced growth rate and therefore
expansion factor at a slightly slower impeller speed (Ns1u) and
suggest that the lower shear stress on the cells may explain
the differences. One confounding factor to their experiment
was that aggregates of MSCs and microcarriers occurred by
the end of the culture period. Thus, there are still issues to be
resolved. V. Jossen et al. performed experiments expanding
MSCs in a bag type of bioreactor to evaluate the differences
between Ns1 and Ns1u between the two types of bioreactors.
They evaluated the maximum power and the shear stress
in the wave type bioreactor, which provides a rhythmic
periodic stress as opposed to the constant stresses provided
in stirred tank bioreactors. Finally, they performed a proof-
of-concept expansion of MSCs to compare yields between
stirred tank and wave type bioreactors. While propagation
of MSCs was possible in both bioreactors, the yield in the
wave type bioreactor was three times lower than the stirred
tank system. In addition, the wave type bioreactor produced
larger aggregates, up to 6mm in size. Their results confirm
earlier reports that Ns1u produces superior propagation of
MSCs in stirred tank bioreactors and that stirred tank
bioreactors are superior for MSC expansion compared to
wave type bioreactors. These data confirm that shear stress
and aggregate formation negatively affect MSC expansion.
When this paper is taken in the context of others within
this special edition, one wonders whether these data can be
extended to other media conditions, such as a chemically
defined medium as discussed in R. J. Emnett et al.’s paper,
or whether these data can be extended to other MSC sources
(as in D. Salzig et al.’s paper). Using mathematical modeling
to optimize MSC manufacturing is a new topic that will be
refined as additional results identify the key variables.
2.1. Application and Optimizing of Stem Cell Therapy. When
treating many forms of hematological cancers or solid
tumors, hematopoietic stem cell transplants reconstitute
hematopoiesis after myeloablative therapy to reduce tumor
burden. Mobilized peripheral blood progenitor cells col-
lected by aphaeresis have become a common means to
treat myeloablative therapy in such patients, replacing even
bone marrow transplant due to the rapid recovery following
transplantation. J. E. V. Meraz et al. compared three different
stem cell mobilization methods in children with malignant
cancers to evaluate which was best for hematopoietic stem
cell mobilization.The threemethodswere cyclophosphamide
(CFA) and hematopoietic growth factor G-CSFwith aphaere-
sis beginning when white blood count (WBC) exceeded
1 × 109/liter (group A), CFA with G-CSF with aphaeresis
beginningwhenWBCexceeded 10× 109/liter (groupB), orG-
CSF alone for 4 days followed by aphaeresis beginning on the
fifth day (group C). In each case, aphaeresis continued until
the target dose of CD34+ cells and MNCs reached 2 × 108/kg
and 4 × 108/kg, respectively. Adverse events, recorded as
hospitalization instances due to neutropenia, were recorded
in the CFA-treated groups (groups A and B), but not in the
G-CSF only group (group C). While group B appears to be
superior to group A for mobilization (total MNC and CD34+
cell number), there were no differences between groups B
and C. J. E. V. Meraz et al. concluded that CFA and G-CSF
mobilization when WBCx exceeds 10 × 109/kg had similar
efficacy to mobilization with G-CSF alone, but G-CSF alone
had fewer adverse events. Since their research did not follow
through with transplantation outcomes, it is unclear whether
the hematopoietic transplant of mobilized blood fromG-CSF
alone (group C) would reconstitute the patients more rapidly
than those patients receiving the combined CFA and G-CSF.
J. E. V. Meraz et al.’s results suggest that the G-CSF protocol
is currently the best preparation for hematopoietic stem cell
transplantation in children.
N. E. Rekittke et al. provided a review of the state of the art
of regenerative medicine therapy for type 1 diabetes mellitus.
Their review focuses on pancreatic islet transplantation and
on undifferentiated MSC transplantation and transdifferen-
tiated MSCs to endoderm or pancreatic progenitor cells.
Pancreatic islet transplants have been evaluated in clinic
studies in the USA and abroad. N. E. Rekittke et al.’s review
covers the major progress in islet transplantation trials
through three iterations: improvements in cadaveric islet
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processing to reduce damage and refinements of immune
suppression in the recipient represent the important stages
of progress. According to N. E. Rekittke et al.’s review, fol-
lowing the latest procedures, the majority of diabetic patients
who receive islet transplantation can expect to become
insulin-independent for up to five years. N. E. Rekittke
et al. discussed unsolved issues of human islet transplants
including the blood-mediated inflammation that impairs islet
function and survival and the need to develop improved
islet isolation protocols which enhance islet function and
survival and reduce demand for cadaveric material to meet
demand. In addition to reviewing translation research on
islet transplantation, N. E. Rekittke et al. discussed the use
of MSCs for type I diabetes therapy. This review indicates
that progress in islet isolation and immune suppression of the
recipient is responsible for the great progress in pancreatic
islet transplantation. If the improved immune suppression
regimes developed for pancreatic islet cell transplantation
also can enable other allogeneic cell transplantation, this
work may have a tremendous impact on the patients needing
tissue transplantation.
Closing out this special issue on manufacturing cells
for cell therapy, S. Zhou et al. provided a state-of-the-art
review on the use of stem cell therapy to treat stress urinary
incontinence (SUI). SUI may affect more than 200 million
people worldwide and disproportionately affects women at a
ratio of 3 : 1. Pregnancy and having a child by vaginal birth
are risk factors for SUI due to functional loss of levator ani
muscles. Similarly, men who have radical prostatectomy are
at increased risk for SUI. The most common and effective
treatments of SUI are bulking agent injections to augment
levator ani function.These bulking agents are associated with
a variety of adverse events suggesting that an alternative
approach, such as the use of stem cells, may assist with
regeneration or repair of levator ani and be effective for
treating SUI. S. Zhou et al. reviewed the preclinical liter-
ature which supports the use of various autologous stem
cell sources, including muscle-derived stem cells, adipose-
derived MSCs, and bone marrow-derived MSCs, for treating
SUI.Thiswork is still in the preclinical stage,mostly, and a few
safety studies were discussed. While injection of stem cells
as bulking agents for levator ani muscle is one direction for
SUI treatment, S. Zhou et al. discuss the tissue engineering
approach, too, which involves the use of scaffolds seeded
with autologous stem cells. Work to date includes preclinical
testing in the rat SUI model as an alternative to surgical
tape. Limitation of both approaches included the need to
improve cell survival after transplantation. This limitation
was identified by the review by N. E. Rekittke et al. also in
this issue, which indicated that the rapid progression and
increased therapeutic impact after islet transplantation in
type I diabetes were coupled with improving the quality of
transplanted cells and improved immune suppression. Since
stem cells transplanted to treat SUI were of autologous origin,
it is likely that larger improvements will be obtained by
improving the cell preparation and transplantation to reduce
cell stress and improve survival after transplantation. While
one might expect that immune suppression would not be
required in the autologous transplantation setting, it is likely
that transient immune suppression is also likely to improve
outcomes in this situation, too.
3. Conclusions
Cellular manufacturing for clinical applications is moving
forward rapidly due to pressing need created by the hundreds
of ongoing clinical trials and due to the research results
providing the fundamental knowledge about barriers and
how to overcome them. In this special issue, topics ranged
from isolation andmanufacturing ofMSCs to critical reviews
of the application of cell therapy for treating type I diabetes
using islet transplantation or treatment of stress induced
urinary incontinence. From reviewing the issues, a key
take-home message is that it is not enough to produce
cells in sufficient numbers. Equally important is to produce
cells that survive and function following transplantation.
In summary, the manufacture of clinical doses of robust
functional cells is one key piece to cell therapy; the other
key is the preparative regime given to the patient to enable
engraftment and function of cells. Looking back in history,
we find this to be a recurrent theme from hematopoietic stem
cell transplantation. Understanding how tomanufacture cells
for clinical purpose is fundamental to improving outcomes
and provides a starting point to evaluate patient preparative
regimens.
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